Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Share-based Compensation: 2021-2025

Historic Share-based Compensation for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $800,764.

  • SAB Biotherapeutics' Share-based Compensation fell 23.65% to $800,764 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 36.30%. This contributed to the annual value of $2.9 million for FY2024, which is 24.21% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Share-based Compensation is $800,764, which was up 27.67% from $627,198 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Share-based Compensation peaked at $2.0 million during Q4 2023, and registered a low of $349,115 during Q1 2021.
  • Its 3-year average for Share-based Compensation is $805,843, with a median of $639,246 in 2023.
  • Per our database at Business Quant, SAB Biotherapeutics' Share-based Compensation skyrocketed by 217.36% in 2023 and then crashed by 66.20% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Share-based Compensation (Quarterly) stood at $651,472 in 2021, then decreased by 3.52% to $628,540 in 2022, then skyrocketed by 217.36% to $2.0 million in 2023, then slumped by 66.20% to $674,135 in 2024, then fell by 23.65% to $800,764 in 2025.
  • Its Share-based Compensation stands at $800,764 for Q3 2025, versus $627,198 for Q2 2025 and $612,951 for Q1 2025.